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Abstract: Increasing evidence suggests that positive affect plays an important role in adaptation
to chronic illness, independent of levels of negative affects like depression. Positive affect may be
especially beneficial for people in the midst of severe stress, such as the diagnosis of human immunodeficiency virus (HIV). As medical treatments for HIV have improved, the number of people
living with HIV has increased, and prevention strategies tailored specifically to people living with
HIV have become a priority. There is a need for effective, creative, client-centered interventions that
can be easily disseminated to community treatment settings, but there are currently few established
interventions for people who are newly diagnosed with HIV. We present the design and methods for a
randomized trial in which we test the efficacy of one such skills-based intervention that targets positive
affect as a novel mechanism of change. The proposed research builds on observational findings of
the important unique functions of positive affect. We aim to determine whether a five-session theoryand evidence-based intervention designed to teach skills for increasing the frequency and intensity
of daily positive affect does so, and whether this intervention has beneficial effects on subsequent
psychological well-being, health behaviors, and physical health up to 15 months after diagnosis with
HIV. This is a randomized controlled trial in a sample of adults recruited within 12 weeks of testing
positive for HIV. The control group is attention-matched, and follow up assessments will be conducted
immediately post intervention (approximately 5 months post diagnosis) and at 10 and 15 months
post diagnosis. This study is an important next step in research concerning the adaptive functions of
positive affect for people coping with HIV or other health-related life stress.
Keywords: positive affect, HIV diagnosis, stress, coping, RCT, intervention, physical health

Introduction
Depression is common in people living with human immunodeficiency virus1 (HIV) and
is associated with substance abuse,2–4 suboptimal medication adherence,5–7 increased
HIV transmission risk behavior,3 and hastened HIV disease progression.8–10 Depression, however, is only part of the emotion picture. Increasing evidence suggests that
positive affect plays an important role in adaptation to chronic illness, independent of
levels of negative affects like depression.11,12 Positive affect may be especially beneficial
for people in the midst of severe stress, such as the diagnosis of HIV.13–16 A growing
body of research shows that positive affect has unique beneficial associations with
psychological and physical health in the context of health-related stress.13,17–21
In the era of HIV treatment as prevention (TaSP), initiating anti-retroviral therapy
(ART) immediately following HIV diagnosis has the potential to optimize health outcomes and reduce transmission rates by promoting sustained HIV viral suppression.22
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However, newly diagnosed HIV-positive persons experience
substantial barriers such as depression and substance use that
hinder linkage to and engagement in HIV medical care.23
Interventions for people with HIV targeting depression,
stress, and associated HIV risk behaviors have shown modest
effects,24–28 but there remains a clear need for improvement.29
The prevalence of comorbid depression in HIV remains
elevated,30 HIV incidence has not dropped appreciably,31 and
a significant proportion of people living with HIV continue
to engage in behaviors that put them at risk for other sexually
transmitted diseases and their partners at risk of infection
with HIV.32
There is a need for effective, creative, client-centered
interventions to realize the potential benefits of TasP and
to facilitate optimal adjustment to HIV. We present the
clinical trial design and rationale for a skills-based intervention for people newly diagnosed with HIV that targets
positive affect as a fundamental and novel mechanism of
change, and promotes resilience in the midst of serious
life stress. This randomized controlled trial (RCT) tests
whether a five-session theory- and evidence-based intervention designed to teach skills for increasing the frequency
and intensity of daily positive affect does so, and whether
these intervention-related increases in positive affect have
beneficial effects on subsequent psychological well-being,
health behaviors, and physical health up to 15 months after
diagnosis with HIV.

The stress of being
diagnosed with HIV
People newly diagnosed with HIV are in the acute phase of
a major stressful life event and face significant challenges
including the need to interact with a complex health care
system; constraints on sexual behavior; decision-making
around disclosure of serostatus to friends, family, and sexual
partners; stigma; and in many cases a struggle to come to
terms with a new identity as someone living with HIV.33,34
The period immediately following human immunodeficiency virus positive (HIV+) serostatus notification is characterized by increases in depression and anxiety.35–41 Even years
after diagnosis, people living with HIV are at elevated risk of
depression,1 which is associated with a number of negative
outcomes including increased sexual risk behavior3 and more
rapid HIV disease progression.8–10 Although interventions
designed to reduce depression in people living with HIV
have met with some moderate success,24,28,42 very few have
targeted those who are newly diagnosed with HIV.
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Stress and the relevance
of positive affect
The intervention we present here focuses on positive affect.
Both theory and research support this approach. We use the
term “affect” broadly, to include any positively or negatively
valenced subjective feeling state. Examples of positive affects
are: happiness, contentment, joy, satisfaction, gratitude,
relief, and pleasure. These are differentiated from negative
affects such as sadness, anger, fear, disgust, shame, and
distress. We are interested in the impact of the intervention
on the frequency and intensity of positive affects and their
impact on subsequent health behaviors and well-being.

Positive affect co-occurs with negative
affect during stressful periods
Positive affect can occur with relatively high frequency, even
in the midst of dire stressful circumstances, and can occur at
the same time that symptoms of depression and distress are
significantly elevated. In our study of caregiver partners of
men with Acquired Immune Deficiency Syndrome (AIDS),
the depression scores of the caregivers in the study were in the
range that would classify them as at risk for clinical depression,
both during caregiving and after the death of the partner.43
However, with the exception of the time immediately surrounding the death of the partner, when asked to report how often
they experienced various positive and negative affects in the
previous week, the participants reported experiencing overall
positive affect as least as frequently as they experienced overall
negative affect.13 Three years after the death of the partner, the
mean depression score of the bereaved caregivers was still
significantly higher than the general population mean.44 Again,
however, positive affect was prevalent.

Adaptational significance of positive
affect during stressful periods
The fact that positive affect co-occurs with negative affect
suggests that positive affect is adaptive in the context
of stress.13–16,45–47 Several empirical studies support this
hypothesis. For example, in a 12-week study of women with
arthritis or fibromyalgia, positive affect was associated with
reduced pain and lowered negative affect, and this relationship was stronger during weeks when participants reported
higher levels of stress.48 Similarly, in a longitudinal study of
widows, daily positive affect buffered the effect of stress on
negative affect. Compared to periods of low stress, positive
affect in periods of high stress predicted lower levels of
negative affect.49
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Laboratory and epidemiological studies suggest positive
affect may also affect physiological outcomes, morbidity,
and mortality. For example, laboratory studies suggest that
positive affect may have beneficial physiological effects in
the context of stress. Fredrickson and Levenson50 induced
negative affect in subjects by showing them a film that elicited
fear. Subjects were then shown one of four films designed to
elicit contentment or amusement (positive affect), sadness
(negative affect), or no affect (neutral condition). Measures
of cardiovascular reactivity indicated that those individuals
who were shown the contentment or amusement film had
faster recovery to baseline than subjects shown the sad or
neutral film.
With respect to morbidity and mortality, studies have
indicated that positive affect is uniquely associated with
lower risk of morbidity and mortality across both chronically
ill and healthy samples.12,51 Mroczek et al52 demonstrated
that although levels of positive and negative affect over the
course of an 8-day diary study were not predictive of 10-year
mortality risk, positive affect reactivity (the extent to which
positive affect dropped in response to a stressful event) was.
Participants who maintained their normal level of positive
affect during days in which they experienced a stressor had
lower mortality than those whose positive affect dropped.
In a sample of men with AIDS, participants with higher
average scores on the positive affect subscale from the Center
for Epidemiological Studies Depression scale (CES-D) had
lower risk (RR) of mortality compared to those with lower
positive affect: RR = 0.89, 95% CI –0.84–0.95.20 When risk
estimates were adjusted for the time-dependent covariates
of CD4, antiretroviral use, and the other subscales of the
CES-D, positive affect remained significantly predictive of
lower risk of AIDS mortality (RR =0.90, CI =0.85–0.97).
These provocative, observational studies suggest that positive
affect may counteract some of the negative physiological and
psychological effects associated with stress and, ultimately,
lead to better health outcomes.

Mechanisms through which
positive affect might influence
clinical outcomes
One pathway through which positive affect may buffer
adverse effects of stress is by increasing coping resources,
such as social support, that enable the individual to cope
better with the stress of HIV in a variety of ways.53 Positive
affect is hypothesized to facilitate social support, and social
support has been shown to be associated with longer survival
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and slower progression of HIV.54,55 In HIV-negative samples,
positive affect is associated with greater social connectedness, when controlling for negative affect and other potential
confounders.56 In another study, Keltner and Bonanno 57
found that bereaved individuals who showed genuine laughs
or smiles (as determined by coding of facial expressions),
while describing their relationship with their deceased
spouse, elicited more positive affect and less frustration
in observers than bereaved individuals who did not show
the genuine laughs or smiles. Perhaps more importantly,
untrained observers indicated that they would be more
likely to offer comfort to those individuals who showed
the genuine laughs or smiles. These findings suggest that
individuals may elicit social support from others by their
displays of positive affect.
Positive affect may influence risk of mortality by bolstering the immune system directly. Various immune parameters
have been shown to be susceptible to influence by experimentally induced, as well as naturally occurring, affective
states.58,59 These findings may not fully generalize to individuals with HIV, but HIV-specific studies suggest that similar
processes occur. Ickovics et al60 found that psychological
resources (an index that combined positive affect, positive
health expectancies, and finding meaning) were associated
with lower risk of mortality and slower CD4 decline, suggesting a possible immune mediator of the link between positive
psychological states and physical health in people with HIV.
Work by Antoni et al demonstrates that stress management
interventions designed to reduce distress in HIV+ samples
improve immune function (eg, increased CD4/CD8 ratio,
increased natural killer [NK] cytotoxicity).54,61–64 Although
stress management interventions both increase positive
affect and decrease negative affect, positive affect has not
been explicitly assessed as a mediator of the association of
stress reduction interventions and improvement in immune
parameters.
Positive affect may also lower risk of morbidity and mortality via improved health behaviors. A study of daily affect and
sexual risk behavior in men who have sex with men (MSM)
demonstrated a unique effect of positive affect: participants
who reported higher positive affect were less likely to engage
in risky sexual behavior, controlling for negative affect and
sexual feelings.65 Positive affect is associated with subsequent reductions in stimulant use among MSM,66 and recent
work demonstrates that positive affect predicts subsequent
engagement in health care among people newly diagnosed
with HIV.17 Positive affect may facilitate attention to and
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processing of health-relevant information, which is a crucial
step in health-promoting behaviors.67,68 These findings extend
evidence on the effects of positive affect into the realm of health
behavior, suggest the possibility that increases in positive affect
may help HIV+ individuals attend to information regarding
their health, and perhaps facilitate more effective health care
utilization. We hypothesize that a positive affect intervention
will increase positive affect which will, in turn, be associated
with improved health behaviors (Figure 1).

Theoretical foundation
of the intervention
The intervention is based on revised stress and coping
theory13,69 and the broaden-and-build theory of positive
emotion.53 Folkman13 proposed a revision to stress and coping
theory that explicitly posits a role for positive affect in the
coping process. According to the original theory,70 the coping process begins when an event is appraised as threatening,
harmful, or challenging. These appraisals are associated
with affect (negative affect in response to threat or harm, a
mix of positive and negative in response to challenge), and
prompt coping. If the event is resolved favorably, a positive
affective state is the result. If the event is resolved unfavorably or if it is unresolved, a negative affective state results
and the coping process continues through reappraisal and
another round of coping. The revised model suggests that
the negative affect associated with unfavorable resolution
motivates coping processes that draw on important goals
and values, including positive reappraisal and goal-directed
problem-focused coping. These coping processes result in
positive affect, which serves important coping functions:
positive affect provides a psychological “time-out” from the
distress associated with chronic stress, and it helps motivate
and sustain ongoing efforts to cope with the negative effects
of the chronic stress. In the context of a new HIV diagnosis,

Broadened cognition and
enhanced resources
(eg, supportive relationships,
problem-solving, resilience)

Enhanced
QOL,
reduced
depression

Enhanced
daily positive
affect

Improved health
behaviors

Improved health
markers/outcomes

Stress and coping
benefits
(challenge vs threat appraisals,
psychological “time out”)

Figure 1 Theoretical model of pathways through which positive affect is associated
with health.
Abbreviation: QOL, quality of life.
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positive affect may facilitate more adaptive coping such as
positive reappraisals where individuals change their thoughts
about stressful circumstances to see them in a more positive
light (eg, “this has made me a stronger person.”) It may also
be that positive affect leads to decreased reliance on avoidantoriented coping strategies (eg, stimulant and other drug use,
and unsafe sexual behavior).
Fredrickson53 proposed the “broaden-and-build” model
of the function of positive affect that complements revised
stress and coping theory. In this model the “broadening”
function of positive affect enables the individual to see
beyond the immediate stressor and possibly come up with
creative alternative solutions to problems. The “building”
function helps to rebuild resources (such as self-esteem and
social support) depleted by enduring stressful conditions.
In contrast to the narrowing of attention and specific action
tendencies associated with negative affect, positive affect
broadens the individual’s attentional focus71–73 and behavioral repertoire.71,74 Repeated experiences of positive affect
build social, intellectual and physical resources that buffer
against the deleterious effects of stress.45,75–77 Although the
broaden-and-build model is not specific to stress, under
stressful conditions the functions of positive affect suggested
by the model become especially important. In the context of
a new HIV diagnosis, positive affect may support adjustment
to living with this chronic illness, and enhance receptivity
to health promotion messages (the broadening function) in
the critical period when newly diagnosed individuals are
establishing new self-care behaviors, including engagement
in health care and safer sexual behaviors.

Design and methods
The study, called IRISS (Intervention for those Recently
Informed of their Seropositive Status), is a five-session positive
affect skills intervention compared to an attention-matched
control condition, in which participants have five sessions of
interviews concerning coping and affect. Both intervention
and control sessions are approximately one hour long and are
administered one-on-one by trained facilitators. Participants in
both conditions have daily home practice over the 5 weeks of
the intervention. At the end of the 15-month assessment period,
participants in the control condition are offered the opportunity
to learn the skills in a self-paced online format.

Participants
Eligibility
To be enrolled in this RCT, participants must: 1) have been
informed they were HIV positive within the past 12 weeks;
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2) speak English or Spanish; 3) be 18 years or older; and
4) have the ability to provide informed consent to be a
research participant. Exclusion criteria include: 1) Inability
to provide informed consent, as evidenced by cognitive
impairment; 2) active psychosis; and 3) unmedicated bipolar disorder. All procedures were approved by the relevant
Human Subjects Committees, and all participants provided
written informed consent.

Study procedures
Recruitment

forms explained that participants would be assigned to one
of two conditions in which they would either “learn skills
to better manage your mood” or “talk about what’s going
on since testing positive.” They were also told they would
have three blood draws to measure CD4 and viral load, and
would receive up to $250 for completing nine visits over
15 months. Interested participants were referred to the study
for screening. Participants who were eligible were then
scheduled for their first assessment session.

Consent, assessments, and randomization

Participants were recruited through HIV testing sites and
clinics, community based organizations, newsletters, and
fliers. Potential participants were informed that the goal of
the study was to find out what’s effective in helping people
cope with a new diagnosis. Study materials and consent

Time relative to HIV
diagnosis

Scheduled assessments take place at four points: Time 1
(baseline) at entry into the study within approximately
3 months post diagnosis; Time 2, at one week postintervention (approximately 5 months post diagnosis);
Time 3 (approximately 10 months post diagnosis);

Study activity
Recruitment

3 months
Time 1 (baseline) assessment
consent, interview, blood draw

Randomization

Control arm
5 weekly in-person sessions
1. Life history
2. Health history
3. Personality and diet
4. Social network and support
5. Meaning and purpose

Intervention arm
5 weekly in-person sessions
1. Positive events, capitalizing, gratitude
2. Mindfulness
3. Positive reappraisal
4. Personal strengths and goals
5. Acts of kindness

Phone evaluation of
intervention sessions

Phone evaluation of control
sessions

5 months

10 months

15 months

Time 2 assessment
interview

Time 3 assessment
interview, blood draw

Time 4 assessment
interview, blood draw

Figure 2 Study recruitment and assessment timeline.
Abbreviation: HIV, human immunodeficiency virus.
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and Time 4 (approximately 15 months post diagnosis.) CD4
and viral load are collected at Time 1,Time 3, and Time 4
(15 months post diagnosis). See Figure 2.
Assessments are conducted one-on-one by trained interviewers who are blind to whether the participant was in the
intervention or the control condition. Assessments consist
of quantitative self-reports on positive and negative affect,
health behaviors, physical health, coping, social support, and
personality; measures are shown in Table 1. Qualitative data are
collected on recent HIV-related stressful events. We use computer assisted personal interviewing and all interviews are audio
recorded for quality control and later transcription and analysis
of the narrative portions. Participants are video recorded during
their stressful event narrative at Times 1, 2, and 4 for coding of
facial expressions of emotion. All study materials have been
translated into Spanish by a certified translator.
At the first assessment session, participants complete
informed consent procedures, have an initial blood draw for
CD4 and viral load, and complete the baseline interview.
Once the baseline assessment is completed, the participant
is randomly assigned to the intervention or control condition
using block randomization with randomly-varying block
sizes of two, four, or six.

Session 1

Content of the intervention

Session 2

Elsewhere, we have detailed the rationale for inclusion
of each of the positive affect skills.78 Briefly, the IRISS
intervention consists of five in-person sessions and one
phone session in which facilitators teach participants eight
empirically-supported behavioral and cognitive “skills” for
increasing positive affect. The eight skills are: 1) noting daily
positive events;79–82 2) capitalizing on or savoring positive
events;83,84 3) gratitude;85–87 4) mindfulness;88–91 5) positive
reappraisal;13,24,42,92–96 6) focusing on personal strengths;97–99
7) setting and working toward attainable goals;42,95,100–103 and
8) small acts of kindness.104–108
The first session begins with an overview of the intervention approach and philosophy. We explicitly acknowledge to
the participant that testing positive for HIV is very stressful
for most people and that we are not advocating a simplistic
“don’t worry – be happy” approach. We explain to participants
that although this is a structured, positive affect skills-building
intervention, they should feel free to discuss their HIV status
or other stressors in the sessions if and when it feels comfortable to them. We also do not require participants to discuss
these issues. We emphasize that our goal is to help participants
give time and attention to the positive experiences and associated emotions, even in the context of serious life stress.

The focus in Session 2 is mindfulness, a state in which one
focuses on the present moment, accepting and acknowledging
it without getting caught up in emotional reactions or ruminative thoughts about the situation. During this session, the facilitator discusses the concept of developing mindfulness through
formal practice, and then practices a formal mindfulness activity with the participant, eg, sitting quietly and paying attention
to the breath, guided by a 10-minute “breath awareness” audio
recording. The audio instructions and the discussion following the breath awareness activity emphasize nonjudgment of
thoughts and feelings that arise during the activity. We give
participants a copy of the audio recording to use for their home
practice (and loan them an audio listening device if they do not
have one readily available for their use). This is followed by
discussion and practice of informal mindfulness (mindfulness
of daily activities such as a phone conversation, walking or
driving, or doing a household chore). Home practice for the
week following Session 2 consists of daily informal mindfulness activities, the 10-minute formal breath awareness activity,
and continuing the gratitude journal and daily emotion reports
that were started in the first week. Participants are instructed
to continue the daily breath awareness activity throughout the
remaining weeks of the intervention.
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In the first session, we focus on positive events, capitalizing, and gratitude. The facilitator explains that even under
extremely stressful conditions, people have the capacity to
experience positive events. The purpose of this part of the
session is to help participants recognize positive events and
the associated positive affect associated with those events.
During this part of the session, the facilitator helps participants understand that when they experience a positive event,
they may capitalize on it by “turning up the volume” (ie,
increasing the intensity) of the associated positive affect by
telling someone about it, writing about it, or simply reflecting on the event and re-experiencing it.83 The home practice
after Session 1 consists of the participant noting a positive
event each day and writing about it (capitalizing), and starting a daily gratitude journal in which the participant lists at
least one thing to be grateful for that day. The gratitude list
continues through the rest of the 5-week intervention period.
Participants are encouraged to list small things (eg, a good
cup of coffee, a smile from a stranger) as well as bigger
things. Finally, participants are asked to complete a daily brief
measure of positive and negative affect on their own (control
group participants also complete this measure).
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Table 1 Outcome, moderator, and intervention-based measures
Measure

Description

Outcomes (Times 1 through 4 unless otherwise noted)
Affect
Modified Differential Emotions
This version of the DES includes a wider range of positive emotions than the original scale. The full scale
Scale (mDES)45
assesses interest, enjoyment, surprise, sadness, anger, disgust, contempt, fear, guilt, shame, shyness,
amusement, awe, contentment, gratitude, hope, love, pride, sympathy, and sexual feelings. Participants
rate how frequently they felt that particular affect in the past week on a five-point scale: 0= never, 1=
hardly, 2= some of the time, 3= often, and 4= most of the time.
Positive and Negative Affect
The PANAS was designed to assess two relatively independent constructs: high activation positive
Schedule (PANAS)117
affect (eg, interested, excited, enthusiastic) and high activation negative affect (upset, irritable, ashamed).
Respondents are asked to indicate how strongly they felt each affect during the past week on a scale from
0= not at all to 4= extremely.
Daily affect diary
Over the 5 weeks of the intervention, both intervention and control group participants report their affect
at the end of each day in a diary format. For this purpose we reworded the mDES described above to
indicate a time frame of “today” instead of “past week.”
Mental health
PRIME-MD118
The Prime MD assesses clinical depression with ten questions regarding depressive symptoms (eg, trouble
falling asleep or staying asleep, poor appetite or overeating, little interest or pleasure in doing things).
A respondent is considered clinically depressed if he/she responds affirmatively to five of nine symptoms
in which one of the symptoms is depressed mood and/or anhedonia (not wanting to do anything).
The Center for Epidemiological
The CES-D was used to measure depressive mood during the past week. The CES-D consists of 20 items
Studies Depression (CES-D) Scale119
which are rated on a four-point scale according to how frequently they were experienced in the previous
week: 1= rarely or none of the time (less than one day), 2= some or a little of the time (1–2 days),
3= occasionally or a moderate amount of time (3–4 days), or 4= most or all of the time (5–7 days).
Spielberger State–Trait Anxiety
The STAI assesses feelings of tension, nervousness, and worry. The first 20 items measure state anxiety
Inventory (STAI)120
(how one feels at the moment) and the last 20 items measure trait anxiety (how one generally feels).
Participants rate the frequency with which they feel or think in ways that indicate presence or absence
of anxiety, eg, “I feel nervous and restless”, or “I feel pleasant” on a four-point scale (almost never,
sometimes, often, almost always).
Perceived Stress Scale121
This four-item version of the scale measures perceived stress with items such as “How often have you felt
difficulties were piling up so high that you could not overcome them?” Participants rate the frequency of
the feeling on a five-point scale (0= never, through 4= very often).
Physical health
Physical symptoms122
Physical symptoms are assessed using a modification of the scale developed by the AIDS Clinical Trials
Group. Participants are asked whether they have experienced each of a series of 38 possible symptoms in
the preceding 30 days and how much the problem bothered them.
CD4 and viral load
Trained phlebotomists obtain approximately 15 mL of blood for CD4 cell count and plasma HIV RNA
viral load using the bDNA assay (Bayer, Emeryville, CA, USA). Assays are run by Quest Diagnostics,
Madison, NJ, USA.
Health behaviors
Sexual risk behaviors123
The sexual behavior questionnaire asks the number of male and female sexual partners in the past 3
months, and whether the participant engaged in receptive anal sex with or without a condom, vaginal sex
with or without a condom, receptive oral sex with or without a condom, and oral sex with or without a
barrier. In addition, for each of the behaviors, the participant is asked how many of the partners he/she
knew were HIV+.
Alcohol/drug use
Alcohol use is assessed by asking how much beer, wine, and liquor the participant consumed in a typical
week during the past month. Drug use is assessed by asking which drugs were used in the past month
to get high and how often in the past month they were used. Response options include cocaine, crack,
amphetamines, downers, marijuana, ecstasy, poppers, and other. Injection drugs are assessed separately
and options include heroin, cocaine, crack, speed, and other. Participants are also asked whether they
shared needles or cookers during the last 3 months, how many people they shared with in the past
3 months, and how many times needles that were not cleaned were shared in the past 3 months. Finally,
participants are asked how many HIV+ people they shared needles or cookers with in the last 3 months.
Medication adherence124,125
Participant adherence to antiretroviral therapy over the past 30 days is assessed using a visual analog scale.
For each HIV medication prescribed, the participant is asked to indicate how much of each drug they
have taken in the past 30 days by placing a line on a 10 cm scale marked from 0% to 100%. From this data,
adherence can be calculated as an average across all medications. In addition, we ask how many doses
were missed in the last 7 days.

(Continued)
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Table 1 (Continued)
Measure

Description

Health attitudes and behaviors
checklist126

This 27-item scale measures two underlying health behavior dimensions: preventative behaviors (eg, exercise)
and risk-taking behaviors (eg, drinking). Responses are made on a five-point scale based on participants’
engagement in that health behavior in the past week. At Times 2, 3, and 4, we also assessed the extent to
which participants were engaging in each of the eight skills taught in the intervention. For example, items such
as “In the past week, how often did you set a goal and work toward it?” (goal setting) or “How often did you
do something nice for someone else?” (acts of kindness) will be embedded with items from the checklist such
as “How often did you exercise?” and “How often did you wear a seatbelt?”

Coping
Ways of Coping Scale127–131

Coping resources
Multidimensional Social
Support Inventory132

Participants are asked to complete the coping items with reference to testing positive for HIV (at Time 1)
or the most stressful situation associated with having HIV that occurred during the previous week
(at Times 2, 3, and 4). The coping scale consists of a range of cognitive and behavioral strategies to cope
with the stressful encounter, eg, “Talked to someone who could do something about the problem,” or
“Went on as if nothing had happened” on a four-point scale (0= does not apply and/or not used; through
3= used a great deal). The participant also responds on other scales hypothesized to be correlated with
positive affect. The 23 assessed forms of coping responses include: confrontive coping, escape–avoidance,
planful problem-solving, positive reappraisal, benefit, growth, mastery of stress, other success, purpose,
positive relations with others, religion and respite, benevolent and negative religious coping, emotional
processing and expression, goal replacement, and maintaining optimism.
This scale assesses practical, emotional, affirmational, HIV, negative, and general support. For each
dimension of support, the respondent is asked whether there is someone to provide that type of support
(yes/no); if yes, who that person is, and their relationship to the respondent. In addition to perceived
availability of each type of support, respondents are asked how often they needed each type of support in
the past month, and how often they actually received it. We will compute separate practical, emotional,
affiliative, HIV, negative, and general support scales.

Moderators (assessed at Time 1 only)
NEO Five-Factor Inventory
The NEO–FFI is a 60-item scale that measures 12 aspects of each of five factors of personality
(NEO–FFI)133
(Neuroticism, Extraversion, Openness, Agreeableness, and Conscientiousness). Neuroticism has been
shown to be associated with negative affect, and extraversion with positive affect, by Rusting and Larsen143
The NEO–FFI has shown excellent reliability and validity in a wide variety of samples and has reasonable
associations with coping (Costa et al144).
Life Orientation Test–Revised
Optimism, or generalized positive expectancies, will be assessed with the ten-item revised version of the Life
(LOT–R)134
Orientation Test–Revised. The LOT–R asks participants to rate their level of agreement with items such as
“in uncertain times, I usually expect the best” on a six-point scale (0= strongly disagree, though 5= strongly
agree). The LOT–R has good reliability, as well as excellent predictive and discriminant validity.
Rosenberg Self-Esteem
Self-esteem was assessed with the RSE, a ten-item measure that asks participants to rate their level of
Scale (RSE)135
agreement to items such as “On the whole, I am satisfied with myself” on a five-point scale (1= strongly
disagree, through 5= strongly agree). The RSE is the most widely used measure of self-esteem and has
been shown to be reliable and valid in a wide variety of samples, including crack users (Falck et al145) and
Spanish-speaking samples (Baños and Guillén146).
World Assumptions
The 32-item WAS assesses people’s worldviews by asking them to rate their level of agreement with
Scale (WAS)136
items such as “Most people can be trusted” and “Anyone can experience a very bad event” on a sevenpoint scale (1= strongly agree, through 6= strongly disagree). The WAS assesses three main categories of
assumptions: benevolence of the world, eg, “There is more good than evil in the world”, meaningfulness
of the world, eg, “Through our actions, we can prevent bad things from happening to us”, and self-worth,
eg, “I am very satisfied with the kind of person I am.” The subscales demonstrate good reliability across
samples (between α =0.81 and 0.87).
Subjective socioeconomic
To assess subjective socioeconomic status, participants are presented with a drawing of a ladder with ten
status137
rungs that is described as follows “Think of this ladder as representing where people stand in our society.
At the top of the ladder are the people who are the best off, those who have the most money, most
education, and best jobs. At the bottom are the people who are the worst off, those who have the least
money, least education, and worst jobs or no job.” They are then asked to place an X on the rung that
best represents where they think they stand on the ladder.
Hassles and Uplifts Scale138
Hassles/uplifts are assessed with a shortened (57-item) version of the Hassles and Uplifts scale. Hassles
are defined as “irritants – things that annoy or bother you” and uplifts are “events that make you feel
good.” For each event on the Hassles/Uplifts scale, the participant indicates whether it has been a hassle
or an uplift since the last interview. The scale is scored by calculating separate hassle and uplift scores.
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Table 1 (Continued)
Measure
Life Experiences Survey

Description
139

Intervention-based mediators
Gratitude Questionnaire–6
(GQ–6)140

Five-Factor Mindfulness Scale141

Coping Self-Efficacy Scale142

Major life events are assessed with a modified version of the Life Experiences Survey. We assess whether
any of the 49 items on the scale occurred since the last assessment. For those that did occur, participants
are asked to rate whether the event had a positive or negative impact.
Gratitude is measured with the GQ–6, a six-item scale that asks participants to rate their level of
agreement with statements such as “I have so much in life to be thankful for” on a eight-point scale
where 1= strongly disagree and 7= strongly agree. We modified the wording of specific items to capture
experiences of gratitude in the past month.
We assessed mindfulness using a revised version of the Five-Factor Mindfulness Scale used in our pilot
work. The scale was shortened to contain 19 Likert-type items, and slight changes were made to the
wording of several items to ensure that they were appropriate for use with participants who had no
prior meditation experience. Respondents are asked to indicate how frequently they experience several
facets of mindfulness, including present-centered awareness and attention (eg, “You find it difficult to stay
focused on what’s happening in the present.” – reverse scored); non-judgment (eg, “You criticize yourself
for having irrational or inappropriate emotions.” – reverse scored); and non-reactivity (eg, “When you
have distressing thoughts or feelings, you just notice them and let them go”). Response options range
from 1= never to 5= always.
Personal strengths in the context of stress were assessed using the 13-item coping self-efficacy scale
which measures self-efficacy in three main areas: using problem-focused coping (eg, “Break an upsetting
problem up into smaller parts”), stopping unpleasant emotions and thoughts (eg, “Make unpleasant
thoughts go away”), and getting support from family and friends (“Get friends to help you with the things
you need”). Participants were asked to rate the degree to which they could perform the listed behaviors
on an eleven-point scale: 0= cannot do at all, 5= moderately certain can do, and 10= certain can do. We
added items to assess self-efficacy in increasing positive affect.

Abbreviations: AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus; HIV+, human immunodeficiency virus positive; RNA, ribonucleic acid;
bDNA, branched deoxyribonucleic acid.

Session 3
In Session 3, we focus on the coping skill of positive
reappraisal. The participant is introduced to the concept of
appraisal, a person’s interpretation or judgment about the
personal significance of an event. The facilitator explains
that because our appraisals determine our emotional reaction
to an event, if we can change our appraisals, we can change
how we feel. Positive reappraisal is a way of dealing with
stress in which the individual makes a positive change in how
an event is interpreted or appraised. Noting that the event
may not be as bad as originally thought, was not as bad as
it could have been, or noting something positive that may
come out of the event are all forms of positive reappraisal
that are likely to be related to increased positive affect in the
face of stress. The facilitator and participant then practice
reappraising recent small events in the participant’s life. We
explicitly do not focus on trying to reappraise the experience of testing positive for HIV. Instead we start with small,
relatively minor events (eg, being late to work; encountering
a rude person on the street; traffic) to develop the skill of
positive reappraisal. Although it is not a proximal goal of the
present intervention given its brief duration, with continued
practice an individual can learn to positively reappraise
virtually any event.109 Home practice consists of reporting a
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relatively minor stressor each day, then listing ways in which
the event can be positively reappraised. The daily formal
mindfulness practice (10 minutes of mindful breathing),
the daily gratitude journal, and the brief emotion reports
continue.

Session 4
In Session 4, we focus on the participant’s personal strengths
and the process of setting (and attaining) achievable goals.
The facilitator asks the participant to list his or her personal
strengths or positive qualities. After the participant lists
them, the facilitator then lists strengths that he has seen in the
participant over the 4 weeks of the intervention. In our pilot
work, this was a powerful positive experience for participants.
It was particularly effective given that participants were in
the midst of the stressful early months after HIV diagnosis.
The next portion of the session concerns defining and setting
attainable goals. We define attainable goals as having four
characteristics: 1) they are realistic and can be reasonably
completed in the allotted time; 2) they are clear; 3) they are
challenging but not impossible or too global; and 4) they
have a clear end point so it is obvious when the goal has been
successfully completed. The facilitator then works with the
participant to set some attainable goals for the coming week.
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The home practice for Session 4 consists of listing a strength
each day and how it was “expressed” behaviorally that day,
working toward one of the goals each day, and noting progress
each day. The 10-minute mindful breathing, the gratitude
journal, and the daily affect reports continue this week.

Session 5
The focus in Session 5 is on altruistic behaviors or small
acts of kindness. The previous 4 sessions encourage participants to focus on themselves. The purpose of Session 5 is to
intentionally focus on other people. The facilitator emphasizes that even though the participant may be going through a
very difficult time in his or her life, he/she can still help other
people through small acts of kindness (including expressing
gratitude to people who performed acts of kindness or helped
care for them). In addition to the mindful breathing, daily
gratitude journal, and daily affect reports, the home practice
for Session 5 consists of doing one small act of kindness each
day and noting it.

Session 6
Session 6 is conducted by phone and focuses on reviewing
the previous week’s home practice, evaluation of each of the
eight skills, evaluation of the intervention overall, and planning for continued practice of the skills.

Content of the control sessions
Participants in the control condition also have five one-onone sessions with a facilitator. The sessions are comparable
in length to the intervention sessions (approximately one
hour) but consist of an interview and do not have didactic
portions or skills practice. These sessions were designed to
remove the positive affect component of the intervention,
while maintaining any nonspecific effects arising from
one-on-one contact with a sympathetic facilitator and an
opportunity to share one’s personal stories and concerns.
The interviews include 1) life history (qualitative); 2) health
history (qualitative), including use of complementary and
alternative medicine and physical activity; 3) personality
and diet questionnaires; 4) social support and social network;
5) meaning and purpose; 6) (via telephone) the ranking of
sessions as to whether participants would recommend the
sessions to a friend; and 7) (via telephone) the participant’s
rating of enjoyment of sessions.
Home practice for the control group consists of brief
daily affect reports over the 5 weeks of the control sessions.
At the start of sessions two through five, the facilitator
reviews the previous week’s affect diary with the participant.
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After the Time 4 assessment (15 months post-diagnosis),
participants in the control condition are given the opportunity
to access an online, self-paced version of the intervention.

Payment of participants
Participants are paid $20 for each intervention/control session, $25 for the first two assessments, and $50 for each of
the assessments at Time 3 and Time 4, for a total of $250
for completing the entire study. In addition, we reimburse
for transportation (eg, cab fare, bus fare, or parking) and
provide a snack for each assessment and intervention/control
session.

Training and intervention fidelity
There were two groups of staff, each of whom required
different training: assessment interviewers (assessors) and
session facilitators. All staff members received a minimum
of 30 hours of training which took place over several weeks
and included: 1) privacy and confidentiality training in Health
Insurance Portability and Accountability Act (HIPAA) security practices and human subjects protection; 2) technology
training, including use of laptops, computer-assisted personal
interview programs, digital audio software, and data tracking
procedures on the study website; 3) training in interviewing
techniques, which addressed building rapport, working with
diverse populations, cultural sensitivity, population-specific
issues and referrals, and basic quantitative and qualitative
interview skills; 4) suicidality assessment protocol; 5)
interview/session roleplays; and 6) site visits to locations
where assessments and control/intervention sessions took
place. Ongoing training provided updates on HIV treatment
and weekly group supervision, and as-needed individual
supervision to address individual cases and procedural
issues for assessors and facilitators. Assessors received
additional training in obtaining informed consent and the
video recording protocol. Facilitators attended a separate
training that included detailed overviews of the intervention
approach and procedures. Specific techniques for adhering
to a manualized intervention while allowing for flexibility to
address individual participant needs were taught, role-played,
and supplemented by instructional readings. Assessors and
facilitators were bilingual and bicultural. The majority of staff
conducting Spanish-language interventions and assessments
were native Spanish speakers.
Following the training, staff conducted mock sessions.
The audio recordings of these sessions were reviewed by the
principal investigator and project director, who then met oneon-one with interviewers/facilitators to provide feedback on
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interviewing and intervention techniques. Mock interviews
were repeated until assessors/facilitators were proficient
with using software, familiar with delivery of quantitative
questionnaires, skilled at conducting the qualitative portion
of the interview and, for the intervention facilitators, were
comfortable and familiar with each of the five intervention
sessions.

Intervention fidelity training
and monitoring
Monitoring of fidelity of intervention and control sessions
during the course of the study included: 1) development of
detailed curriculum manuals for each of the sessions; 2) intensive training; 3) incorporation of mock training sessions that
enabled us to ensure all facilitators met performance criteria
for intervention/control session delivery; and 4) audio recording of sessions. Audio recordings of facilitator sessions were
reviewed by the project director to assess adherence to the
protocol, delivery, interpersonal skills, facilitator/participant
rapport, and session flow.

Measures
Detailed descriptions of the measures are provided in
Table 1.

Planned analyses
The primary outcome measure is positive affect. Our first aim
is to determine the efficacy of the intervention for increasing
positive affect at Times 2, 3, and 4. The second aim tests positive affect as a mediator of intervention effects on psychological well-being (eg, depression), health behaviors (eg, HIV
transmission risk, engagement in care, medication adherence)
and physical health (eg, CD4, viral load, symptoms). The
third aim tests moderation of intervention effects by baseline
characteristics such as gender, race/ethnicity, and personality
(see Figure 1).
We will first examine baseline characteristics of the
sample, stratified by experimental group, to ensure that
key variables (positive affect, mental and physical health,
and demographics) are indeed evenly distributed in the
randomization. Before testing hypotheses, we will also
examine the proportion of missing data at each time point
in order to address any concern regarding possible bias due
to differential attrition. Completers and dropouts will be
compared on baseline variables using independent t and
Fisher’s exact tests. Variables showing substantial group
differences at baseline will be candidates for inclusion as
covariates in tests of hypotheses.
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Given that this study is a treatment evaluation, we will
conduct intention-to-treat analyses. We will supplement
these analyses with dose-response analyses, using ordinary
or logistic regression, depending on whether outcomes are
continuous or dichotomous, to test whether various measures
of participation (eg, number of sessions attended, days of
homework completed) affect outcomes.
Aim 1. Determine the efficacy of the Intervention for
those Recently Informed of their Seropositive Status (IRISS)
to increase frequency and intensity of our primary outcome,
positive affect, during the intervention and at 5, 10, and 15
months after diagnosis. Tests of intervention effects will be
conducted with multiple-group growth models, with coefficients chosen to reflect the hypothesized pattern of change.
We expect frequency and intensity of positive affect, as
measured, respectively, by the modified Differential Emotions
Scale (mDES) and Positive and Negative Affect Schedule
(PANAS) (see Table 1), to increase for the intervention group
over the course of the intervention, and to be maintained
thereafter. The most specific manifest-variable test of the
hypothesis as a whole is the difference between groups on
the contrast between baseline and the following three time
points. On a more piecemeal basis, differences in means
or in change scores can be tested with independent t-tests
comparing the intervention to the control group.
Aim 2. Test the effects of IRISS on psychological and
physical health and health behaviors, and determine whether
increases in positive affect are responsible for improvements
in these outcomes. The tests of effects here are the same as
those in Aim 1, with different outcome variables. Some, like
clinical depression, are binary, but these can be handled by
Mplus (Muthén and Muthén, Los Angeles, CA, USA) through
probit regression. Others, like viral load, are known to have
strong positive skew and will be (log) transformed before
analysis. Determining whether increases in positive affect
are responsible for these changes requires mediation analysis.
Since we expect both the outcomes and these potential
“mediators” to be products of the intervention, with perhaps
no clear separation in time, the first step in these analyses will
be to examine whether changes in positive affect precede or
coincide with changes in the outcomes. MacKinnon et al110
conducted a Monte Carlo study of 14 procedures for testing
mediation effects, found the classic method of Baron and
Kenny111 unacceptably weak, and recommended testing the
product of the coefficients in the mediation path by reference to the distribution of the product of two normal variates
(which is not itself normal). As recommended by Shrout and
Bolger112 we will use Mplus to bootstrap the product term.
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Given the dependency of indirect effects on the time interval,
for multiwave models we will compute overall, rather than
time-specific, indirect effects.113
Aim 3. Evaluate the extent to which personality, sex, or
race/ethnicity moderate the effects of IRISS on these outcomes. Since we will be exploring moderation and mediation
separately, moderation can be tested simply by the addition of
interaction terms, with components appropriately centered.

Discussion
The first few months after HIV diagnosis provide a window
of opportunity for intervention in which participants are
establishing new patterns of sexual risk and health behaviors.
Although the period immediately following diagnosis is
associated with significantly elevated levels of depression
and anxiety, there are few interventions designed expressly
for people newly diagnosed with HIV.
Based on increasing evidence from our research team
and others that positive affect has adaptive functions in
the context of health-related stress, we developed and are
testing a theory-based positive affect skills intervention
for people newly diagnosed with HIV. By emphasizing
the importance of positive affect in the stress process we
may appear to minimize the pain and serious individual
and societal consequences associated with major stressful
events. We are not advocating a simplistic “don’t worry, be
happy” approach, nor do we believe that simply increasing
positive affect will prove to be a cure-all for the very real
and complex issues facing people newly diagnosed with
HIV. Such a stance could easily degenerate into blaming the victim for not thinking the positive thoughts that
may prevent depression or other negative consequence of
enduring stress.
However, an intervention to increase positive affect in the
months after testing positive for HIV may set the stage for
a cascade of adaptive consequences. In addition, the focus
on positive affect will likely make the proposed intervention more attractive to providers and participants alike, and
serve as an antidote to the increasingly pervasive “prevention
fatigue”.114–116
Further, in pilot testing this intervention we learned that
participants were not the only ones whose positive affect
increased; facilitators, staff, and investigators also experienced increases in positive affect. Ultimately, given the high
levels of stress, distress, and depression documented in this
population of people newly diagnosed with HIV, we consider
increasing positive affect to be an inherently worthwhile
intervention goal.
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